Cargando…
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 continues to have a serious impact on public health worldwide. Most patients develop mild to moderate symptoms and recover without requiring special treatment, but up to 15% develop severe (dyspnea, hypoxia, lung involvement) or critical symptom...
Autor principal: | Bellino, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586661/ https://www.ncbi.nlm.nih.gov/pubmed/36259490 http://dx.doi.org/10.1080/07853890.2022.2133162 |
Ejemplares similares
-
Tuberculosis among migrant populations in the European Union and the European Economic Area
por: Odone, Anna, et al.
Publicado: (2015) -
Is tuberculosis crossing borders at the Eastern boundary of the European Union?
por: van der Werf, Marieke J., et al.
Publicado: (2013) -
Good practices and challenges in addressing poliomyelitis and measles in the European Union
por: Kinsman, John, et al.
Publicado: (2018) -
The Economic Impact of COVID-19 Treatment at a Hospital-level: Investment and Financial Registers of Brazilian Hospitals
por: Beck da Silva Etges, Ana Paula, et al.
Publicado: (2021) -
External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients
por: Halalau, Alexandra, et al.
Publicado: (2020)